

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

MEDA PHARMACEUTICALS INC.,	)	
	)	
Plaintiff,	)	
	)	
v.	)	C.A. No. _____
	)	
AUROBINDO PHARMA LIMITED and	)	
AUROBINDO PHARMA USA, INC.,	)	
	)	
Defendants.	)	
	)	

**CORPORATE DISCLOSURE STATEMENT OF  
PLAINTIFF MEDA PHARMACEUTICALS INC.**

Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, Defendant Meda Pharmaceuticals Inc. (“Meda”) states as follows:

1. Meda is a wholly owned subsidiary of Meda AB.
2. Mylan N.V., a publicly held company, indirectly owns more than 10% of Meda AB’s stock.

Date: February 12, 2019

*Of Counsel:*

Deepro R. Mukerjee  
Lance Soderstrom  
**KATTEN MUCHIN ROSENMAN LLP**  
575 Madison Avenue  
New York, NY 10022-2585  
(212) 940-8800  
deepro.mukerjee@kattenlaw.com  
lance.soderstrom@kattenlaw.com

/s/ Amy Luria  
Amy Luria  
**CRITCHLEY, KINUM & DENOIA, LLC**  
75 Livingston Avenue  
Roseland, New Jersey 07068  
Telephone: (973) 422-9200  
Fax: (973) 422-9700  
aluria@critchleylaw.com

Jitendra Malik, Ph.D.  
Alissa M. Pacchioli  
**KATTEN MUCHIN ROSENMAN LLP**  
550 S. Tryon Street, Suite 2900

Charlotte, NC 28202-4213  
jitty.malik@kattenlaw.com  
alissa.pacchioli@kattenlaw.com